Risks following infection versus vaccination

UK, (England), Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study https://www.bmj.com/content/374/bmj.n1931 https://www.bbc.co.uk/news/health-58347434 Prof Julia Hippisley-Cox People vaccinated with first doses, 16 or over N = 29,121,633 Oxford-AstraZeneca (ChAdOx1 nCoV-19) N = 19,608,008 Pfizer-BioNTech (BNT162b2mRNA) N = 9,513,625 People testing positive SARSCoV-2 N = 1,758,095 Within 28 days of three exposures First dose of the ChAdOx1 nCoV-19 vaccine First dose of the BNT162b2 mRNA vaccine SARS-CoV-2 positive test For every 10 million people vaccinated with the AstraZeneca An extra 107 would be hospitalised or die from thrombocytopenia (1 in 93,459) 9 times lower than the risk following an infection An extra 66 would be hospitalised or die from blood clots in the veins Nearly 200 times lower than the risk following an infection For every 10 million people vaccinated with the Pfizer An extra 143 extra strokes would be seen (1 in 69,930) 12 times lower than the risk following an infection Myocarditis and pericarditis Chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm 52 million doses to 12–29 years 1,226 reports of myocarditis after mRNA vaccination 42,414 One in 42,414 Data demonstrate increased risks, particularly within the seven days following the second dose The observed risk is higher among males under 40 years of age compared to females and older males Risk is highest in males 12 through 17 years of age Learn more about your ad choices. Visit megaphone.fm/adchoices